Who We Are
Welcome to the Biotech Bulletin brought to you by US Specialty Formulations (USSF), VaxForm and QYNDR.
US Specialty Formulations (USSF) is a team of pioneers focusing on tailored pharmaceuticals and leading the charge in developing custom pharmaceutical solutions to address unique patient needs. From rare diseases to complex conditions, we specialize in formulating medications that optimize efficacy, enhance patient outcomes and manufacture clinical materials through accessible innovation.
VaxForm is at the forefront of vaccine innovation and revolutionizes how we approach immunization. Our cutting-edge research and development efforts focus on crafting advanced vaccine formulations and delivery mechanisms to bolster effectiveness and broaden accessibility, safeguarding communities against infectious diseases worldwide.
QYNDR is at the frontier of immunization with its groundbreaking oral vaccine platform. Leveraging innovative technology, QYNDR introduces a new era in vaccination, offering an accessible and efficient alternative to traditional injection-based vaccines. Through oral delivery, QYNDR enhances convenience, compliance and efficacy, heralding a transformative approach to preventive medicine and global health initiatives.
Latest News – Expansion Plans
US Specialty Formulations (USSF) announces a $15 million expansion to modernize biopharma operations at its Lehigh Valley facility. This expansion will significantly increase production capacity, create new jobs, and boost the local economy. The project includes the construction of new clean room suites and the installation of advanced packaging and product equipment. With this investment, USSF aims to strengthen its position as a leader in the pharmaceutical industry and support the development of innovative new treatments.
Click here to read moreWhat We Do
- More than 45 years of combined experience
- Team of scientists and experts with diverse solutions, applications and approaches
- Problem solvers
- Year-on-year growth
- Successfully completed COVID-19 Clinical Trial Phase I
- Botanical solution formulated for multiple uses, developed from Sarracenia Purpurea (pitcher plant Sarapin)
- Clinical materials
- Contract manufacturing
- Pharmaceuticals
- Delivery systems
- Feeding mills
- Drug development
Meet The Founders
Kyle Flanigan, Ph.D. is CEO and Co-Founder of USSF, bringing more than 25 years of experience in pharmaceutical and medical performance materials development stages. He consults with clients, providing robust and stable solutions and services for formulation, scale-up technology, contingency planning, supply-chain issues, quality systems implementation and new facility design. He brings this knowledge and guidance to USSF’s manufacturing and development teams, enabling clients and their pharmaceutical and medical developments on the best path to market.
Dr. Flanigan’s career path has enabled him to develop strong skills for global organization building, process integration and setting regulatory strategy with cross-functional teams in the Pacific Rim, the United States and Europe.
Garry Morefield, Ph.D. is the President of VaxForm LLC and COO and Co-Founder of USSF. He has more than 20 years of experience with all stages of development and production in the pharmaceuticals and biologics industry. He has worked on a variety of bacterial and viral vaccine targets from pre-clinical development through clinical phases, including seasonal and pandemic influenza, pneumococcal and meningococcal conjugates, meningococcal group B, C. difficile, hepatitis B, inactivated polio, diphtheria, tetanus, pertussis, as well as combination vaccine products.
Dr. Morefield is a recognized expert in aluminum adjuvants hosting multiple presentations at research conferences and private company workshops, as well as an expert witness in patent prosecutions.
Stay tuned for further updates. Be sure to whitelist US Specialty Formulations to ensure you receive our latest news and announcements directly in your inbox.
